Innovations in Oncology: Breast Cancer

Have you seen the new evidence supporting antibody-drug conjugates (ADCs) for the treatment of triple-negative breast cancer (TNBC)? Can you recognize treatment directions based on biomarkers, such as HER2-low and HER2 overexpression?

This educational series examines the rapidly evolving landscape of breast cancer treatment. Tune in to hear our globally renowned experts break down current and emerging ADCs that could benefit your patients with TNBC and HER2 breast cancer.

Provided by:

In Partnership with:

8

LikeLikedUnlike

Episodes 1-13 of 13

MinuteCE®
Innovations in Oncology Learning Center: From Guidelines to Practice—Breast Cancer
- William J. Gradishar, MD
  Peer
- Erica L. Mayer, MD, MPH
  Peer
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 credits 10 episodes
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
MinuteCE®
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
MinuteCE®
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
- Erica L. Mayer, MD, MPH
  Peer
1.50 program credits
Management of HR+, HER2- High-Risk EBC
MinuteCE®
Management of HR+, HER2- High-Risk EBC
- Erica L. Mayer, MD, MPH
  Peer
1.50 program credits
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
MinuteCE®
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
- Erica L. Mayer, MD, MPH
  Peer
1.50 program credits
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
MinuteCE®
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits
Management of HER2-Low MBC Following First-Line Disease Progression
MinuteCE®
Management of HER2-Low MBC Following First-Line Disease Progression
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits
The Evolving Treatment Landscape for MBC: Emerging Therapies
MinuteCE®
The Evolving Treatment Landscape for MBC: Emerging Therapies
- William J. Gradishar, MD
  Peer
1.50 program credits
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
MinuteCE®
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits
Emerging Treatment Approaches for EBC
MinuteCE®
Emerging Treatment Approaches for EBC
- William J. Gradishar, MD
  Peer
1.50 program credits
Expert Viewpoint: Optimizing Breast Cancer Treatment
MinuteCE®
Expert Viewpoint: Optimizing Breast Cancer Treatment
- William J. Gradishar, MD
  Peer
- Erica L. Mayer, MD, MPH
  Peer
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits
Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer
CME/CE
Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer
- William J. Gradishar, MD
  Peer
- Javier Cortes, MD, PhD
  Peer
- Hope S. Rugo, MD, FASCO
  Peer
Utilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationship Between ADCs and HER2
CME/CE
Utilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationship Between ADCs and HER2
- William J. Gradishar, MD
  Peer
- Javier Cortes, MD, PhD
  Peer
- Hope S. Rugo, MD, FASCO
  Peer

Program Chapters

Segment Chapters

Playlist:

Recommended